EUVIMEDEUVIMED entdecken
Crossref

Impact of Early Intervention on the Developmental and Ocular Outcome of Patients With Cobalamin C Deficiency Identified Through Newborn Screening

Anna T Reischl-Hajiabadi iD, Laura Guilder, Michal Inbar-Feigenberg, Liali Aljouda, Celia Atkinson, Vivian Cruz, Nicole Martin, Ajoy Vincent, Eva Mamak, Janet Marcadier, Andreas Schulze

Journal of Inherited Metabolic Disease · 2026-03 · 49 (2)

DOI: 10.1002/jimd.70162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 23.02.2026. Verfasst von Anna T Reischl-Hajiabadi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Genetics and Genome Biology, the Hospital for Sick Children, Toronto, Canada. Hauptthemen laut MEDLINE: Vitamin B 12 Deficiency, Homocystinuria, Hydroxocobalamin, Eye Diseases. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the implementation of newborn screening (NBS), developmental outcomes in individuals with Cobalamin C (CblC) deficiency remain variable, and ocular manifestations are common. Therapy with hydroxocobalamin (OH‐Cbl) is recommended by clinical guidelines, and increasing the dosage may improve outcomes. In this study, we evaluated the developmental and ocular outcomes of individuals with CblC deficiency identified through NBS. We conducted a retrospective analysis of 21 patients with CblC deficiency who were referred after abnormal NBS results and were followed at our center for a median of 9.0 years (0.9–16.1 years). Treatment was initiated at a median age of 9 days (range 4–18 days). All patients received OH‐Cbl at a median dosage of 0.16 mg/kg/d (range 0.03–0.36 mg/kg/d) over the follow‐up period and followed a regular diet. Thirteen patients presented with neonatal symptoms, but at the last follow‐up, 52% of individuals had disease‐related symptoms, including seizures in one patient and developmental impairment in 10 cases. Neuropsychological testing was performed in 15 patients and showed cognitive impairment in more than half of them. Ten individuals had ocular manifestations with a median age of onset of 17.5 months (range 3–50 months); of these, nine patients had developmental impairment. 48% of patients were asymptomatic at the last follow‐up. Despite early intervention, a substantial proportion of individuals exhibited developmental impairments or ocular manifestations, and neonatal onset appears to be associated with disease severity. Early treatment seems to prevent epilepsy. The potential role of genotype–phenotype correlations, particularly in relation to dosage response, warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitamin B 12 DeficiencyHomocystinuriaHydroxocobalaminEye DiseasesHumansInfant, NewbornNeonatal ScreeningFemaleMaleRetrospective StudiesChildInfantAdolescentChild, PreschoolTreatment Outcome

Stichwörter der Autor:innen

CblCinherited metabolic diseasesneonatal screeningneurocognitive outcomeophthalmologic manifestations

Substanzen

Hydroxocobalamin

Autor:innen und Institutionen

  • Genetics and Genome Biology, the Hospital for Sick Children, Toronto, Canada.
  • Department of Pediatrics I, Division of Pediatric Neurology and Metabolic Medicine, Heidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Heidelberg, Germany.
  • Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Departments of Ophthalmology and Vision Sciences, The Hospital for Sick Children, the University of Toronto, Toronto, Ontario, Canada.
  • Division of Psychology, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Newborn Screening Ontario, Ottawa, Ontario, Canada.

ORCID-Profile: Anna T Reischl-Hajiabadi

Zitieren

APA

Reischl-Hajiabadi, A. T., Guilder, L., Inbar-Feigenberg, M., Aljouda, L., Atkinson, C., Cruz, V., Martin, N., Vincent, A., Mamak, E., Marcadier, J., & Schulze, A. (2026). Impact of Early Intervention on the Developmental and Ocular Outcome of Patients With Cobalamin C Deficiency Identified Through Newborn Screening. Journal of Inherited Metabolic Disease, 49(2). https://doi.org/10.1002/jimd.70162

Vancouver

Reischl-Hajiabadi AT, Guilder L, Inbar-Feigenberg M, Aljouda L, Atkinson C, Cruz V, et al. Impact of Early Intervention on the Developmental and Ocular Outcome of Patients With Cobalamin C Deficiency Identified Through Newborn Screening. Journal of Inherited Metabolic Disease. 2026;49(2). doi:10.1002/jimd.70162

BibTeX
@article{ReischlHajiabadi2026,
  author = {Reischl-Hajiabadi, Anna T and Guilder, Laura and Inbar-Feigenberg, Michal and Aljouda, Liali and Atkinson, Celia and Cruz, Vivian and Martin, Nicole and Vincent, Ajoy and Mamak, Eva and Marcadier, Janet and Schulze, Andreas},
  title = {Impact of Early Intervention on the Developmental and Ocular Outcome of Patients With Cobalamin C Deficiency Identified Through Newborn Screening},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2026},
  volume = {49},
  number = {2},
  doi = {10.1002/jimd.70162}
}
Kostenlos starten →